IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1-25 out of 1262.

1 | 2 | 3 | 4 | 5 > >>

Public Release: 23-Feb-2017
Human Gene Therapy
AAV gene delivery vectors and cancer -- The debate continues
Overwhelming evidence from the biomedical literature shows that adeno-associated virus 2 (AAV2), a viral vector often used to deliver therapeutic genes, is not associated with cancer and, in fact, may protect against cancer.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2250
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 23-Feb-2017
Journal of Experimental Medicine
Why is pancreatic cancer so hard to treat? Stroma provides new clues
Why are pancreatic tumors so resistant to treatment? One reason is that the 'wound'-like tissue that surrounds the tumors, called stroma, is so dense, likely preventing cancer-killing drugs from reaching the tumor. A team has now discovered heterogeneity in the fibroblast portion of the stroma, opening up the possibility of targeted treatment.
Cold Spring Harbor Cancer Center Support Grant, NIH/National Cancer Institute, The Lustgarten Foundation, Cold Spring Harbor Laboratory Association, National Institutes of Health

Contact: Peter Tarr
tarr@cshl.edu
516-367-5055
Cold Spring Harbor Laboratory

Public Release: 23-Feb-2017
Clinical Cancer Research
PI3K/mTOR inhibitors may be effective against some uterine sarcomas
The protein P-S6S240 may serve as an indicator of poor prognosis for patients with a hard-to-treat type of uterine sarcoma called leiomyosarcoma, and preclinical data suggest that patients whose tumors have this protein may respond to PI3K/mTOR inhibitors.
Prague's biobanking grant project, Swedish Labour Market Insurance and Swedish Medical Research Council, Western Norway Regional Health Authority (Helse Vest RHF), Norwegian Cancer Society, Norwegian Research Council

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research

Public Release: 23-Feb-2017
International Journal of Cancer
Tumor protein could hold key to pancreatic cancer survival
A diagnosis of pancreatic cancer is often a death sentence because current chemotherapies have little impact on the disease.

Contact: Annie Rahilly
arahilly@unimelb.edu.au
61-390-355-380
University of Melbourne

Public Release: 23-Feb-2017
Clinical Cancer Research
Anti-aging gene identified as a promising therapeutic target for older melanoma patients
Scientists at The Wistar Institute have shown that an anti-diabetic drug can inhibit the growth of melanoma in older patients by activating an anti-aging gene that in turn inhibits a protein involved in metastatic progression and resistance to targeted therapies for the disease.
Melanoma Research Foundation, American Cancer Society, Miriam and Sheldon Adelson Research Foundation, Ira Brind Associate Professorship

Contact: Darien Sutton
dsutton@wistar.org
215-898-3988
The Wistar Institute

Public Release: 22-Feb-2017
PLOS ONE
Incarceration linked to excess burden of cancer, new study finds
People who spend time in jails and prisons are more likely to develop certain types of cancer than the general population in Ontario, according to a study published today in the open-access journal PLOS ONE. They were also more than 50 percent more likely to die from cancer than the general population in Ontario, the study found.

Contact: Kelly O'Brien
obrienkel@smh.ca
416-864-5047
St. Michael's Hospital

Public Release: 22-Feb-2017
Cell Reports
Scientists identify chain reaction that shields breast cancer stem cells from chemotherapy
Working with human breast cancer cells and mice, researchers at Johns Hopkins say they have identified a biochemical pathway that triggers the regrowth of breast cancer stem cells after chemotherapy.
US Department of Defense, American Cancer Society

Contact: Shawna Williams
shawna@jhmi.edu
410-955-8236
Johns Hopkins Medicine

Public Release: 22-Feb-2017
Nature
Nature study suggests new therapy for Gaucher disease
Scientists propose in Nature blocking a molecule that drives inflammation and organ damage in Gaucher, and maybe other lysosomal storage diseases, as a possible treatment with fewer risks and lower costs than current therapies. Reporting their data Feb. 22, the international research team conducted the study in mouse models of lysosomal storage disease and in cells from blood samples donated by people with Gaucher disease.

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center

Public Release: 22-Feb-2017
Nature
CAR T cells more powerful when built with CRISPR, MSK researchers find
Researchers from Memorial Sloan Kettering Cancer Center have harnessed the power of CRISPR/Cas9 to create more-potent chimeric antigen receptor (CAR) T cells that enhance tumor rejection in mice.
Lake Road Foundation, Mr. William H. and Mrs. Alice Goodwin, Commonwealth Foundation for Cancer Research, Stand Up To Cancer, American Association for Cancer Research, Lymphoma and Leukemia Society, NYSTEM, NIH/National Cancer Institute

Contact: Caitlin Hool
hoolc@mskcc.org
Memorial Sloan Kettering Cancer Center

Public Release: 22-Feb-2017
Clinical Cancer Research
Measuring patients' muscles to predict chemotherapy side effects
Researchers at the University of North Carolina Lineberger Comprehensive Cancer Center report in the journal Clinical Cancer Research that measuring patients' muscle mass and quality could potentially help doctors better identify patients at high risk for toxic side effects that could require hospitalizations.

Contact: Laura Oleniacz
laura_oleniacz@med.unc.edu
919-445-4219
UNC Lineberger Comprehensive Cancer Center

Public Release: 21-Feb-2017
PLOS ONE
Israeli, Palestinian researchers cooperate to find risks for B cell non-hodgkin lymphoma
Most epidemiological studies of Non-Hodgkin's Lymphoma (NHL) have been carried out in North American and European populations, with very few focusing on B-cell NHL in Middle Eastern populations. Now, Israeli and Palestinian researchers have conducted a large scale epidemiological study examining risk factors for B-NHL and its sub-types in the Israeli and Palestinian populations, finding some risk factors common to both groups, and some that are unique to only one population.
MERC/USAID, Israel Science Foundation, Hadassah University Hospital Compensatory Fund

Contact: Dov Smith
dovs@savion.huji.ac.il
972-258-82844
The Hebrew University of Jerusalem

Public Release: 21-Feb-2017
Oncogene
The way breast cancer genes act could predict your treatment
A Michigan State University breast cancer researcher has shown that effective treatment options can be predicted based on the way certain breast cancer genes act or express themselves.
National Institutes of Health, Susan G. Komen Foundation

Contact: Sarina Gleason
sarina.gleason@cabs.msu.edu
517-355-9742
Michigan State University

Public Release: 21-Feb-2017
Nature Communications
Danish discovery opens up for new type of immunological treatment of cancer
Researchers from Aarhus University have found an important piece of the puzzle leading towards an understanding of how our innate immune system reacts against viral infections and recognises foreign DNA, for example from dying cancer cells. The discovery may prove to be of great importance for immunological treatment of cancer as well as autoimmune diseases in the future.
The Lundbeck Foundation, Danish Council for Independent Research, Augustinus Foundation, Frode V. Nyegaard og Hustrus Foundation

Contact: Martin Roelsgaard Jakobsen
mrj@biomed.au.dk
45-87-16-78-46
Aarhus University

Public Release: 21-Feb-2017
The Lancet
One-off bowel scope cuts cancer risk for at least 17 years
A one-off bowel screening test reduces the risk of developing bowel cancer by more than one-third and could save thousands of lives.
Medical Research Council, National Institute for Health Research, Cancer Research UK

Contact: Fiona Dennehy
fiona.dennehy@cancer.org.uk
020-346-96770
Cancer Research UK

Public Release: 21-Feb-2017
Annals of Oncology
Death rates from cancer will fall faster in men than in women in Europe in 2017
Death rates from cancer in the European Union (EU) are falling faster in men than in women, according to the latest predictions for European cancer deaths in 2017, published in the leading cancer journal Annals of Oncology. Compared with 2012, death rates in men will fall by just over eight percent to 132 per 100,000 of the population in 2017, while in women the decline will be around four percent to 84.5 per 100,000.
Italian Association for Cancer Research, MIUR (Ministero dell'Istruzione, dell'Universita e della Ricerca), SIR (Scientific Independence of Young Researchers) 2014 grant, the European Cooperation in Science and Technology--COST Action BM1204 EU-Pancreas

Contact: Emma Mason
wordmason@mac.com
European Society for Medical Oncology

Public Release: 21-Feb-2017
International Journal of Radiation Oncology, Biology, Physics
Penn expert calls for shorter radiation use in prostate cancer treatment
Men with prostate cancer can receive shorter courses of radiation therapy than what is currently considered standard, according to Justin Bekelman, M.D., an associate professor of Radiation Oncology, Medical Ethics, and Health Policy at the University of Pennsylvania's Perelman School of Medicine and Abramson Cancer Center.
NIH/National Cancer Institute

Contact: John Infanti
john.infanti@uphs.upenn.edu
215-301-5221
University of Pennsylvania School of Medicine

Public Release: 21-Feb-2017
Cancer Epidemiology, Biomarkers & Prevention
Hispanic cancer mortality varies among ethnic groups
Cancer mortality rates vary considerably within the growing Hispanic population in the United States, with significant differences among the major Hispanic ethnic groups.
NIH/National Institute of General Medical Sciences

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research

Public Release: 21-Feb-2017
Molecular Therapy - Oncolytics
Using a rabbit virus to treat multiple myeloma
Treating multiple myeloma (MM) with myxoma virus (MYXV) eliminated a majority of malignant cells in preclinical studies, report investigators at the Medical University of South Carolina (MUSC) and elsewhere in an article published online on Dec. 7, 2016 by Molecular Therapy -- Oncolytics. Furthermore, introduction of MYXV had no impact on the bone marrow compartment and elicited a strong immune response that eradicated disease in some animals.
NIH/National Institute of Allergy and Infectious Diseases,NIH/National Cancer Institute, American Cancer Society, Hollings Cancer Center's Cancer Center, South Carolina Clinical and Translational Research Institute

Contact: Heather Woolwine
woolwinh@musc.edu
843-792-7669
Medical University of South Carolina

Public Release: 21-Feb-2017
British Journal of Nutrition
Unlocking the heart-protective benefits of soy
A product of digesting a micronutrient found in soy may hold the key to why some people seem to derive a heart-protective benefit from eating soy foods, while others do not. Japanese men who are able to produce equol -- a substance made by some types of "good" gut bacteria when they metabolize isoflavones (micronutrients found in dietary soy) -- have lower levels of a risk factor for heart disease than their counterparts who cannot produce it.
National Institutes of Health, Japanese Ministry of Education, Culture, Sports, Science and Technology, Pitt Public Health's Department of Epidemiology

Contact: Allison Hydzik
HydzikAM@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences

Public Release: 21-Feb-2017
Journal of Clinical Oncology
Hormonal maintenance therapy may improve survival in women with chemo-resistant rare ovarian or peri
For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance therapy (HMT) may significantly improve survival, according to a new study from researchers at The University of Texas MD Anderson Cancer Center.

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center

Public Release: 21-Feb-2017
ASCO-Society for Immunotherapy in Cancer
Gut bacteria associated with cancer immunotherapy response in melanoma
Melanoma patients' response to a major form of immunotherapy is associated with the diversity and makeup of trillions of potential allies and enemies found in the digestive tract, researchers at The University of Texas MD Anderson Cancer Center report at the ASCO-Society for Immunotherapy in Cancer meeting in Orlando.

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center

Public Release: 21-Feb-2017
American Journal of Preventive Medicine
E-cigarettes popular among smokers with existing illnesses
In the US more than 16 million people with smoking-related illnesses continue to use cigarettes. According to a new study in the American Journal of Preventive Medicine, current and former smokers who suffer from disease are more likely to have reported using an e-cigarette, meaning these patients may see e-cigarettes as safer or less harmful than combustible cigarettes and a way to reduce the risks posed by traditional smoking.
National Institute on Drug Abuse, NIH/National Heart Lung and Blood Institute

Contact: Jillian B. Morgan
ajpmmedia@elsevier.com
734-936-1590
Elsevier Health Sciences

Public Release: 21-Feb-2017
Nature Communications
Discovery of a new gene critical in the development of lung and pancreatic cancers
Researchers at the Center for Applied Medical Research (CIMA) of the University of Navarra (Spain) have identified a critical gene, FOSL1, in the development of lung and pancreatic cancer. The work, published in Nature Communications, shows that the inhibition of FOSL1 brings about a great reduction in the size of the tumors in the lungs and pancreas. Thus, the results present this gene as a new molecular target to which new drugs should be directed.

Contact: Miriam Salcedo
miriamsalcedo@unav.es
34-948-194-700
Universidad de Navarra

Public Release: 21-Feb-2017
Proceedings of the National Academy of Sciences
Penn/Wistar study finds 'sweet spot' where tissue stiffness drives cancer's spread
Researchers from the University of Pennsylvania and The Wistar Institute have now found that physical forces exerted between cancer cells and the ECM are enough to drive a shape change necessary for metastasis. Those forces converge on an optimal stiffness that allows cancer cells to spread.
NIH/National Cancer Institute, National Institutes of Health, National Science Foundation

Contact: Evan Lerner
elerner@upenn.edu
215-573-6604
University of Pennsylvania

Public Release: 21-Feb-2017
Cancer Research
Prostate cancer cells grow with malfunction of cholesterol control in cells
Advanced prostate cancer and high blood cholesterol have long been known to be connected, but it has been a chicken-or-egg problem. Now a team led by researchers at the Duke Cancer Institute have identified a cellular process that cancer cells hijack to hoard cholesterol and fuel their growth. Identifying this process could inform the development of better ways to control cholesterol accumulation in tumors, potentially leading to improved survival for prostate cancer patients.
National Institutes of Health, Stewart Rahr Prostate Cancer Foundation Young Investigator Award, Department of Defense

Contact: Sarah Avery
sarahaver@gmail.com
919-660-1306
Duke University Medical Center

Showing releases 1-25 out of 1262.

1 | 2 | 3 | 4 | 5 > >>

  Search News Releases

     

 

EurekAlert!